Treatment of polycystic ovary syndrome with insulin-lowering agents

Abstract

Early diagnosis and therapy of the underlying insulin resistance of heritable polycystic ovary syndrome (PCOS), often manifested at menarche, facilitate the reduction and/or reversal of the reproductive and metabolic morbidity of PCOS, as well as reduce the risk factors for cardiovascular disease. PCOS is characterised by oligoamenorrhoea, clinical and biochemical hyperandrogenism, infertility, recurrent miscarriage, insulin resistance, hyperinsulinaemia, gestational diabetes, impaired glucose tolerance, Type 2 diabetes, morbid obesity, hypertension, hypofibrinolysis, hypertriglyceridaemia, low levels of high density lipoprotein-cholesterol and a sevenfold risk increase in cardiovascular disease. Insulin sensitising-lowering agents reduce insulin resistance and hyperinsulinaemia, reverse PCOS endocrinopathy and ameliorate the reproductive, metabolic and cardiovascular morbidity of the disorder. The largest literature on the subject discusses metformin. Improved pregnancy outcomes in women with PCOS receiving metformin may be attributed to its ability to reduce insulin resistance, hyperinsulinaemia and hypofibrinolytic plasminogen activator inhibitor activity by the enhancement of folliculogenesis and improvement of oocyte quality.

• atherothrombosis
• hyperandrogenism
• gestational diabetes
• hyperandrogenism
• hyperlipidaemia
• hypertension
• hypofibrinolysis
• impaired glucose tolerance
• infertility
• insulin resistance syndrome
• insulin sensitising-lowering agents
• metabolic syndrome
• miscarriage
• obesity
• oligoamenorrhoea
• polycystic ovary syndrome
• pregnancy
• Type 2 diabetes